ECE2018 Guided Posters Diabetes Translational (12 abstracts)
The role of oncostatin m in the development of type 2 diabetes associated with obesity
Siri Taxeras 1 , Irene Piquer-Garcia 1 , Silvia Pellitero 2 , Rocío Puig 2 , Eva Martínez 2 , Jordi Tarascó 2 , Pau Moreno 2 , Ernest Bombuy 2 , Carmen Higueras 2 , Paloma Malagón 2 , Carles Lerin 3 , Manel Puig-Domingo 1 & David Sanchez-Infantes 1
1Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain; 2Hospital Germans Trias i Pujol, Barcelona, Spain; 3Hospital Sant Joan de Déu, Barcelona, Spain.
Background: Obesity can lead type 2 diabetes (T2D), however there are patients with obesity who present euglycemia. The mechanisms by which T2D appears have not been fully elucidated. Oncostatin m (OSM) is a proinflammatory cytokine, member of the IL-6 family, which is increased in obesity in mice and humans, and impairs browning in mice. Here, we aim at evaluating the potential role of OSM in the development of T2D in patients with obesity.
Material and methods: A cohort of 25 patients across a range of BMI (24–60 kg/m2) were recruited for this study. Patients were classified in 3 groups according to clinical data: 1) Healthy normal-weight controls; 2) Normoglycemic obesity (fasting glycemia <100 mg/dl); 3) Hyperglycemic obesity (fasting glycemia >100 mg/dl). Subcutaneous white adipose tissue (sWAT) was collected for RNA analysis.
Results: As expected, we found that OSM mRNA levels increased in sWAT from patients with obesity compared to healthy controls. Moreover, we observed for the first time that OSM mRNA expression was elevated in patients with obesity who had hyperglycemia compared to those who had obesity but normal glucose values (P=0.04). In addition, a direct correlation was found between OSM gene expression and insulin and triglyceride levels.
Conclusions: Low-grade chronic inflammation during obesity may lead to the development of T2D. OSM is a cytokine with an important role in several inflammatory diseases. Here, we propose that this cytokine could also be involved in the development of insulin resistance. Therefore, OSM might be a novel target molecule for the prevention/treatment of T2D associated to obesity.
Volume 56
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more